A Successful Treatment of Anterior nodular Scleritis with Topical Corticosteroids in a patient with Crohn's ColitisGalanopoulos M1,4*, Nikolaidou E2, Sarafis A3, Liatsos C4 and Kalafatis E4
- *Corresponding Author:
- Galanopoulos M
Department Of Gastroenterology
General Hospital of Athens Evaggelismos
Ypsilantou 45-47, kolonaki, GR 10676, Athens, Greece
Tel : +302132041609
E-mail: [email protected]
Received date: October 31, 2015; Accepted date: January 23, 2016; Published date: January 29, 2016
Citation: Galanopoulos M, Nikolaidou E, Sarafis A, Liatsos C, Kalafatis E (2016) A Successful Treatment of Anterior nodular Scleritis with Topical Corticosteroids in a patient with Crohn’s Colitis. J Inflam Bowel Dis & Disord 1:101. doi:10.4172/jibdd.1000101
Copyright: © 2016 Galanopoulos M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Scleritis is a chronic, painful, potentially blinding disorder that may also involve the cornea, the adjacent episclera and the unveil tract. It is often associated with ocular complications (corneal changes, glaucoma, cataracts) and in up to 50% of patients it is accompanied by an underlying systemic illness such as rheumatoid arthritis , Wegener’s granulomatosis or inflammatory bowel diseases (IBDs). It is considered to be a relatively rare extra-intestinal ocular manifestation of IBDs (about 2%). This case report represents an anterior nodular scleritis in a patient with Crohn’s colitis who had been primarily treated with topical ophthalmic corticosteroids, and was on infliximab therapy for the underlying disease for three years. Treating a mild form of scleritis with topical corticosteroids could be a reasonable therapeutic option for patients receiving an anti-TNF agent for subjacent inflammatory bowel disease, in order to avoid further immunosuppression with systemic anti-inflammatory drugs.